FDA Halts Clinical Trial for Regenxbio's Hunter Syndrome Gene Therapy

The U.S. Food and Drug Administration has issued a clinical hold on Regenxbio's experimental gene therapy, RGX-121, for Hunter Syndrome. This regulatory action was prompted by the observation of spinal scan abnormalities in five participants, raising safety concerns for the ongoing trial and impacting its future.